Conjugate Or Complex Patents (Class 424/193.1)
  • Patent number: 11324809
    Abstract: Provided are: a pharmaceutical composition for curing, treating, or preventing a disease involving a biological mechanism controlled by a dendritic cell immunoreceptor, in which the pharmaceutical composition contains a carbohydrate modifying enzyme as an active ingredient; and a method of curing, treating, or preventing a disease involving a biological mechanism controlled by a dendritic cell immunoreceptor.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: May 10, 2022
    Assignee: Tokyo University of Science Foundation
    Inventors: Yoichiro Iwakura, Tomonori Kaifu
  • Patent number: 11298376
    Abstract: A method of treating cancer can include administering a polyplex of a double stranded RNA and a polymeric conjugate. The polymeric conjugate can consist of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety can be conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: April 12, 2022
    Assignee: TARGIMMUNE THERAPEUTICS AG
    Inventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
  • Patent number: 11267853
    Abstract: The invention features a compositions and methods for inducing an immune response to targeted cells. The compositions induce targeting of a cell by positioning carbohydrate epitopes on the surface of the cell by conjugation of the epitope to a pH-triggered membrane peptide (pHLIP®).
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: March 8, 2022
    Assignees: University of Rhode Island Board of Trustees, Yale University
    Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Anna Moshnikova, Donald M. Engelman
  • Patent number: 11141377
    Abstract: Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: October 12, 2021
    Assignee: Infectious Disease Research Institute
    Inventors: Christopher B. Fox, Amit Praful Khandhar, Neal Van Hoeven, Jesse H. Erasmus, Susan S. Lin
  • Patent number: 11094518
    Abstract: Laser ablation devices and methods including laser ablation are provided. The ablation devices can include a deep UV laser. Dual-laser ablation devices are also provided. Biomolecules can be ablated using a combination of deep UV laser and nanoelectrospray, resulting in protonated sample molecules.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: August 17, 2021
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY
    Inventors: Kermit King Murray, Fabrizio Donnarumma, Oluwaremilekun Lawai
  • Patent number: 11020449
    Abstract: The present invention refers to the use of the peptide defined by the amino acid sequence G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A, named GK-1, to be used as an antitumor and antimetastatic agent or for the treatment of cancer, specifically of basal cell carcinoma, squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma, and preferably for the treatment of breast cancer.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: June 1, 2021
    Assignee: UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO
    Inventors: Edda Lydia Sciutto Conde, Gladis del Carmen Fragoso Gonzalez, Diana Torres Garcia, Jacquelynne Brenda Cervantes Torres, Rene Alvaro Segura Velazquez, Armando Perez Torres, Karen Manucharyan
  • Patent number: 10994049
    Abstract: The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: May 4, 2021
    Assignee: ALLERGAN INDUSTRIE, SAS
    Inventors: Gabriel N. Njikang, Xiaojie Yu, Futian Liu, Sumit Paliwal, Nicholas J. Manesis
  • Patent number: 10993997
    Abstract: The present disclosure relates to methods for profiling subject specific and personalized T cell receptor (TCR) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of T cell receptors to subject specific neoantigens. In addition, the techniques herein may identify the antigenic targets of T cell receptors in the context of tumor neoantigens. Moreover, the present disclosure enables the discovery of T cell targets in numerous diseases, with implications for understanding the basic mechanisms of the mammalian immune response and for developing antigen-specific diagnostic markers and therapies. Finally, cloned TCRs can be used to formulate personalized immunotherapies for those inflicted with a disease, such as cancer.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: May 4, 2021
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nir Hacohen, Catherine Ju-Ying Wu, Edward F. Fritsch, Ute E. Burkhardt
  • Patent number: 10844098
    Abstract: The invention provided a method for preparing a bacterial polysaccharide-modified recombinant fusion protein and use of the bacterial polysaccharide-modified recombinant fusion protein. The method comprises: co-expressing a recombinant fusion protein and the Neisseria meningitidis O-oligosaccharyltransferase PglL in an O-antigen ligase gene-defective bacterium, and linking a polysaccharides endogenous or exogenous for the bacterium to the recombinant fusion protein by the O-oligosaccharyltransferase PglL, to obtain the bacterial polysaccharide-modified recombinant fusion protein. The protein can be used for preparing antibodies against bacterial polysaccharides and vaccines.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: November 24, 2020
    Assignee: Institute of Biotechnology, Academy of Military Medical Sciences, China
    Inventors: Jun Wu, Chao Pan, Peng Sun, Hengliang Wang, Bo Liu, Zhehui Peng, Li Zhu, Shaohong Chang, Xin Gong, Erling Feng, Bin Wang, Ming Zeng
  • Patent number: 10787652
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: September 29, 2020
    Assignee: Pfizer Inc.
    Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
  • Patent number: 10774181
    Abstract: The invention is directed to multi-functional N-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a N-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless N-maleimidyl polymer derivatives.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: September 15, 2020
    Assignee: Nektar Therapeutics
    Inventor: Xiaoming Shen
  • Patent number: 10772324
    Abstract: The invention relates to an aqueous adjuvant composition containing: a) one or more alkyl glucamides of formula (I) wherein R1 is a linear or branched alkyl group with five to nine carbon atoms and R2 is an alkyl group with one to three carbon atoms; b) water; c) optionally a co-solvent. The invention further relates to the use of such compositions to increase the biological activity of pesticides, preferably of herbicides, and to produce an aqueous pesticide composition.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: September 15, 2020
    Assignee: Clariant International Ltd.
    Inventor: Andreas Wacker
  • Patent number: 10732181
    Abstract: Disclosed is a method for detecting lipid bilayer membrane particles or fragments thereof, having predetermined molecules existing on surfaces thereof, in a biological sample collected from a subject, the method comprising: adding to the biological sample a dye that stains a lipid bilayer membrane; adding a substance that specifically binds to the predetermined molecules; trapping the substance bound to the predetermined membrane molecules and separating unbound components; and detecting the separated stained lipid bilayer membrane particles or fragments thereof by measurement of the dye emission spectrum. The specific binding substance is conjugated to a magnetic bead or binds to a magnetic bead, the trapping and separating steps are performed magnetically, and the particle size of the magnetic bead is equal to or less than the minimum detection sensitivity of the measurement system.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: August 4, 2020
    Assignee: NIHON KOHDEN CORPORATION
    Inventors: Yutaka Nagai, Masashi Takao, Masami Ito
  • Patent number: 10669318
    Abstract: The present invention relates to a process for conjugation of an antigen.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: June 2, 2020
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Pierre Duvivier, Ollivier Francis Nicolas Gavard
  • Patent number: 10640547
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: May 5, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10618896
    Abstract: Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses. Also provided are methods of making pharmaceutical compositions containing these compounds. The present disclosure also describes methods of use for the alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, and pharmaceutical compositions containing these compounds for the treatment of disease in a subject.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: April 14, 2020
    Assignee: Dynavax Technologies Corporation
    Inventors: Stewart D. Chipman, John Demattei, Radwan Kiwan, Melissa A. Kachura
  • Patent number: 10588962
    Abstract: The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: March 17, 2020
    Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., UNIVERSITÄTSSPITAL BASEL
    Inventors: Peter H. Seeberger, Pierre Stallforth, Gennaro De Libero, Marco Cavallari
  • Patent number: 10576132
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: March 3, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10543232
    Abstract: A polyplex of a double stranded RNA (dsRNA) and a polymeric conjugate consists of a linear polyethyleneimine (PEI) covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety is conjugated via a linker to a targeting moiety capable of binding to a cancer antigen. Exemplary cancer antigens include epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and prostate surface membrane antigen (PSMA).
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: January 28, 2020
    Assignee: TargImmune Therapeutics AG
    Inventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
  • Patent number: 10438128
    Abstract: The invention concerns the field of human auto-immune and/or inflammatory diseases, and more specifically the use of arsenic compounds for the preparation of drugs intended for the treatment and/or prevention of skin injuries associated with auto-immune and/or inflammatory diseases in a human subject. The invention concerns an arsenic compound As2O5 for use in the treatment and/or prevention of skin injuries associated with auto-immune and/or inflammatory diseases in a human subject, a pharmaceutical composition comprising an arsenic compound As2O5, preferably for the treatment and/or prevention of skin injuries associated with auto-immune diseases in a human subject, and products containing an arsenic compound As2O5 and an arsenic compound As2O3 as a combination product for simultaneous, separated or time-spread use in the treatment and/or prevention of skin injuries associated with auto-immune diseases in a human subject.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: October 8, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS-SUD 11
    Inventors: Mohcine Benbijja, Pedro Bobe
  • Patent number: 10385165
    Abstract: The invention is directed to multi-functional N-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a N-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless N-maleimidyl polymer derivatives.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: August 20, 2019
    Assignee: Nektar Therapeutics
    Inventor: Xiaoming Shen
  • Patent number: 10364298
    Abstract: A novel lipoteichoic acid (LTA) was isolated from C. difficile, the structure of which is illustrated below wherein n is an integer between 1 and 20, R3 and R4 are independently selected from C 14:0, C 16:0, C 16:1, C 18:0 or C18:1 fatty acid or any combination thereof wherein one of COR3 or COR4 may be replaced by H. Further described are conjugates comprising the novel LTA and vaccines produced using the isolated LTA and the LTA conjugates. The invention also encompasses methods of conferring immunity against C. difficile comprising administering a vaccine of the invention, and methods of detecting C. difficile using the isolated LTA of the invention.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: July 30, 2019
    Assignee: National Research Council of Canada
    Inventors: Christopher Reid, Susan M. Logan, Evguenii Vinogradov, Andrew Cox, Jean-Robert Brisson
  • Patent number: 10342858
    Abstract: The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA3/SSEA4/GloboH associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globo-series glycosphingolipid SSEA3/SSEA4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globo-series synthetic pathway. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: July 9, 2019
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Patent number: 10335395
    Abstract: This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 2, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • Patent number: 10279019
    Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: May 7, 2019
    Assignee: STC.UNM
    Inventors: Alan Remaley, John T. Schiller, Marcelo Amar, Bryce Chackerian
  • Patent number: 10226537
    Abstract: This invention relates to transduction of cargo molecules into living cells, such as protein transduction, in particular a delivery molecule for transduction of a cargo into a cell comprising: a cargo-binding molecule and/or a cargo; a glycosaminoglycan (GAG) binding element, which is capable of binding to GAG on the surface of the cell; and a protein transduction domain. Methods of transduction, methods of producing or modifying cargo for transduction, delivery molecules for transduction and methods of treatment using transduction, or using transduced cells are also provided.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: March 12, 2019
    Assignee: The University of Nottingham
    Inventors: James Dixon, Kevin Shakesheff, Chris Denning
  • Patent number: 10206981
    Abstract: A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 19, 2019
    Assignee: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Patent number: 10207012
    Abstract: The present invention provides novel drug discovery platforms and methods for treating type I diabetes.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: February 19, 2019
    Assignee: Biocrine AB
    Inventors: Per-Olof Berggren, Alejandro Caicedo
  • Patent number: 10183074
    Abstract: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: January 22, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis Brito, Michelle Chan, Andrew Geall, Derek O'Hagan, Manmohan Singh
  • Patent number: 10166277
    Abstract: The invention relates to compositions of vault complexes for use as adjuvants for stimulating a cellular immune response to an antigen, for example a tumor antigen, and methods of using the vault complexes in the treatment of diseases, such as cancer.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: January 1, 2019
    Assignees: The Regents of the University of California, The United States of America represented by the Department of Veterans Affairs
    Inventors: Leonard H. Rome, Valerie A. Kickhoefer, Sherven Sharma, Steven M. Dubinett, Isaac Yang, Linda M. Liau, Kathleen A. Kelly, Jian Yang, Upendra K. Kar, Cheryl Champion, Janina Jiang
  • Patent number: 10138474
    Abstract: The present invention relates to a composition comprising a lysosomal enzyme conjugated to a negatively charged scavenger receptor ligand. In some embodiments, the lysosomal enzyme is conjugated to the scavenger receptor ligand by way of a linker. The present invention also relates to a composition comprising lysosomal enzyme encapsulated by a liposome, said liposome externally comprising a negatively charged scavenger receptor ligand. The invention further encompasses a method of treating a lysosomal storage disease with the compositions listed above. The invention further encompasses a method of treating a lysosomal storage disease with an acylated, acetylated, or aconitylated lysosomal enzyme.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: November 27, 2018
    Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
    Inventors: David H. Calhoun, Lane Gilchrist
  • Patent number: 10131697
    Abstract: The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum Apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines against Plasmodium parasites, including P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. Nucleic acid molecules encoding said fusion proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such fusion proteins; antibodies induced or generated by the use of said fusion proteins or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy; methods for producing such fusion proteins; compositions and methods for using such fusion proteins for the prevention and treatment of malaria are also encompassed by the present disclosure.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: November 20, 2018
    Assignee: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung E.V.
    Inventors: Alexander Boes, Holger Spiegel, Gueven Edgue, Veronique Beiss, Markus Sack, Andreas Reimann, Rainer Fischer
  • Patent number: 10092891
    Abstract: TGF-? growth factor and its latent complex are conjugated to magnetic micro- or nanoparticles and to magnetic micro- or nanodiscs. By exposing the resulting conjugates to magnetic fields, the TGF-? growth factor can be released from its latent complex in vivo, potentially making it useful in tissue engineering and regenerative medicine. And by exposing a conjugate of TGF-? growth factor and a magnetic particle to a sufficiently strong, radiofrequency magnetic field, the TGF-? growth factor can be denatured and thereby deactivated, potentially making it possible to avoid triggering tumorigenesis, atherosclerosis, fibrotic disease, and cancer.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: October 9, 2018
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Adam Monsalve, Jon P. Dobson
  • Patent number: 10059746
    Abstract: The present invention provides a process called “Immune Banking” that enhances vaccine efficacy by exploiting existing humoral responses. The process involves tagging new antigens with molecular markers recognized by an existing antibody response. This recognition of the tagged vaccine components enhances adaptive immune responses to the new vaccine.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: August 28, 2018
    Assignee: University of Iowa Research Foundation
    Inventors: Gail Bishop, Tony Vanden Bush
  • Patent number: 10047116
    Abstract: The present invention regards nanoparticles comprising a sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin, which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: August 14, 2018
    Assignee: MX Adjuvac AB
    Inventors: Bror Morein, Saideh Berenjian, Kafei Hu
  • Patent number: 10039816
    Abstract: The present invention provides novel enterobactin-carrier protein conjugates and salmochelin-carrier protein conjugates, such as compounds of Formula (I), and salts thereof. The present invention also provides compositions, kits, and methods that involve the compounds of Formula (I) and are useful in inducing an immune response, treating a bacterial infection and/or inflammatory bowel disease in a subject, preventing a bacterial infection and/or inflammatory bowel disease in a subject, or inhibiting the growth of or killing a bacterium.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: August 7, 2018
    Assignees: Massachusetts Institute of Technology, The Regents of the University of California
    Inventors: Elizabeth Marie Nolan, Phoom Chairatana, Manuela Raffatellu, Martina Sassone Corsi, Araceli Perez-Lopez
  • Patent number: 10028911
    Abstract: Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a Cmax of MTX between 5% and 50% of the Cmax of an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 24, 2018
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Louie Daniel Garcia, Lois Gibson, William Joseph Lambert, Benjamin W. Li, Liangjin Zhu
  • Patent number: 10011815
    Abstract: The invention pertains to a method to sporulate coccidial oocysts purified from animal faeces (5), the method comprising providing the purified oocysts as a layer (40) on a supporting surface (22), maintaining the layer at least intermittently in an oxygen containing gaseous environment (60) having a relative humidity of at least 15% and maintaining the temperature of the oocysts between 19° C. and 37° C. The invention also pertains to sporulated oocysts obtained with this method and to a vaccine containing such sporulated oocysts.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: July 3, 2018
    Assignee: Intervet Inc.
    Inventors: Theodorus Petrus Maria Schetters, Koen Gevers
  • Patent number: 9974830
    Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: May 22, 2018
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Jill Wykosky, Denise Mazess Herpai
  • Patent number: 9951107
    Abstract: The invention relates to compositions of vault complexes containing recombinant membrane lytic proteins, such as an adenovirus protein VI lytic domain, and methods of using the vault complexes to facilitate delivery and entry of a biomolecule into a cell or subject.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: April 24, 2018
    Assignees: The Regets of the University of California, The Scripps Research Institute
    Inventors: Leonard H. Rome, Valerie A. Kickhoefer, Glen Nemerow, Cheng-Yu Lai, Christopher Wiethoff, Mu Han
  • Patent number: 9949927
    Abstract: The present invention provides bis-polymer lipid-peptide conjugates containing a hydrophobic block and headgroup containing a helical peptide and two polymer blocks. The conjugates can self-assemble to form helix bundle subunits, which in turn assemble to provide micellar nanocarriers for drug cargos and other agents. Particles containing the conjugates and methods for forming the particles are also disclosed.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: April 24, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ting Xu, He Dong, Jessica Shu, Nikhil Dube
  • Patent number: 9931399
    Abstract: The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: April 3, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Barbara Baudner, Derek O'Hagan, Manmohan Singh, Simone Bufali
  • Patent number: 9884920
    Abstract: The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (FAPY-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to FAPY-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: February 6, 2018
    Assignee: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
    Inventors: Eric Holmes, Gary Ostrander
  • Patent number: 9884114
    Abstract: Provided herein are methods for rational design of nicotine haptens. More particularly, provided herein are methods for designing, selecting, and synthesizing nicotine haptens and nicotine hapten conjugates. Also provided herein are novel nicotine haptens and methods for using nicotine haptens to treat nicotine addiction.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: February 6, 2018
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Yung Chang, Sidney Hecht, Joseph Leal, Viswanath Arutla, Xiaowei Liu, Sriram Sokalingam
  • Patent number: 9878028
    Abstract: The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: January 30, 2018
    Assignee: Sanofi Pasteur SA
    Inventors: Pierre Chouvenc, Alain Francon
  • Patent number: 9828465
    Abstract: The invention is directed to multi-functional N-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a N-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless N-maleimidyl polymer derivatives.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: November 28, 2017
    Assignee: Nektar Therapeutics
    Inventor: Xiaoming Shen
  • Patent number: 9814759
    Abstract: The present invention provides a pharmaceutical composition containing recombinant hemoglobin protein or tetramer or dimer or subunit for tissue oxygenation and treating cancer. The recombinant hemoglobin protein or tetramer or dimer or subunit-based therapeutic agent is also effective for treating cancer. The recombinant hemoglobin or tetramer or dimer or its subunit moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The recombinant hemoglobin or tetramer or dimer or its subunit-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer.
    Type: Grant
    Filed: June 28, 2015
    Date of Patent: November 14, 2017
    Assignee: Cheer Global Ltd.
    Inventors: Bing Lou Wong, Norman Fung Man Wai, Sui Yi Kwok
  • Patent number: 9770414
    Abstract: Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a Cmax of MTX between 5% and 50% of the Cmax of an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: September 26, 2017
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Louie Daniel Garcia, Lois Gibson, William Lambert, Benjamin W. Li, Liangjin Zhu
  • Patent number: 9737615
    Abstract: The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting molecules, and targeting molecules.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: August 22, 2017
    Assignee: PharmalN Corporation
    Inventors: Gerardo M. Castillo, Elijah M. Bolotin
  • Patent number: 9676819
    Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: June 13, 2017
    Assignee: INNAVAC PTY LTD
    Inventors: David Charles Jackson, Amabel Tan, Weiguang Zeng